Are B‐type natriuretic peptide (BNP) and N‐terminal‐pro‐BNP useful in neonates?
B‐type natriuretic peptide (BNP) and N‐terminal‐pro‐BNP (NTpBNP) have a major role in screening and diagnosis of cardiac disease and monitoring of the treatment response in children and adults. This review discusses the evidence underpinning the potential benefits of these natriuretic peptides in neonatology. They may serve as a useful adjunct to echocardiography in the diagnosis of patent ductus arteriosus and its response to treatment and the diagnosis of persistent pulmonary hypertension of the newborn. However, more work is needed to explore the possible roles of BNP/NTpBNP in the management of sepsis and monitoring of cardiac performance in neonates.
ACESSO AO ARTIGOhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2675431
- Ventricular natriuretic B-type peptide (BNP) after pediatric heart transplantation
- B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity
- B‐type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans
- Management of diastolic heart failure in older adults: B-type natriuretic peptide was not mentioned
- B-type natriuretic levels in critically ill patients: critically misleading?